

PRESS RELEASE

Published: 27-06-2023

Inhalation Sciences receives Purchase Order worth 125.8 KEURO from international distributor for Asia

Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.8 KEuro (1.47 MSEK), from an international distributor for Asia. The new order is for PreciseInhale, ISAB's unique aerosol generation system, with additional modules.

PreciseInhale is unique within inhaled drug development as a 'precision dosing' system. Unlike standard 'tower testing' systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development.

ISAB has recently increased the focus of its commercial activities around its Inhalation Research Services (IRS) capabilities. Nevertheless, the company's unique platform still attracts direct purchase interest, often from academic research organizations looking to be able to offer state-of-the-art testing and data.

ISAB CEO Manoush Masarrat: "We have been working to finalize this deal for a while with our distributor and it is great to see it come to fruition. We are delighted to expand our presence in a region as exciting and dynamic as Asia. We look forward to seeing the work that will come out of this purchase."

Find out more about PreciseInhale here.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and Dissolv/t® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 27 June 2023.